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1. Introduction  
Autoimmune hepatitis (AIH) is a progressive, chronic inflammatory liver disease of 
unknown etiology that occurs in children and adults with a prevalence of female. This 
clinical syndrome is caused by an immune response that is misdirected against self or 
foreign antigens that resemble self-antigens, leading to a progressive inflammatory and 
fibrotic process of the liver (Krawitt, 2006; Czaja, 2001, 2007a, 2007b; Vergani et al, 2002; 
Manns & Vogel, 2006, Vergani & Mieli-Vergani, 2008). The complications of AIH are the 
same as any other progressive liver disease. Primary hepatocellular carcinoma is a known 
consequence; in some patients, chronic hepatitis progresses to cirrhosis and, ultimately, to 
carcinoma. Liver transplantation is required when end stage liver disease develops (Krawitt, 
2006).  
AIH has been widely described in liver transplant recipients with and without AIH before 
transplantation. In the first scenario the term of recurrent AIH has been proposed, while de 
novo AIH implies the development of AIH in the graft of a recipient who did not have the 
disease before. De novo and recurrent AIH develop in the clinical context of immune 
suppression. Consequently the diagnosis may depend more heavily on the exclusion of 
other causes for allograft dysfunction rather than on the presence of criteria for the 
diagnosis of classic AIH codified by the international scoring system. The careful analysis of 
these cases provides exiting and exceptional opportunities to study the pathogenesis of AIH 
in a human model. To understand the bases for recurrent and de novo AIH after liver 
transplantation, it is necessary to apply current hypotheses of pathogenesis for classic 
disease.  
2. Pathogenic mechanism of AIH 
The pathogenesis of AIH remains uncertain, but conditions that favor its emergence are 
becoming clearer. Environmental agents like viruses, toxins or drugs (Krawitt, 2006, Czaja et 
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al, 1992, Czaja, 1999a) may trigger a cascade of T-cell mediated events against liver antigens 
in a context of genetic predisposition (Czaja & Manns, 1995; Alvarez, 1999, Molmenti et al, 
2002; Sanchez-Urdazpal et al, 1992), leading to a progressive necroinflammatory liver disease. 
Although multiple genes are probably involved in a predisposition to AIH, human 
leukocyte antigen (HLA) genes appear to play the dominant role (Donaldson et al 1998, 
Donaldson, 2002). Type 1 AIH, characterized by circulating antinuclear antibodies, smooth 
muscle antibodies, antiactin antibodies, atypical perinuclear antineutrophilic cytoplasmic 
antibodies and autoantibodies against soluble liver antigen and liver-pancreas antigen is 
associated with the HLA DR3 serotype, particularly among white patients. In Japan the 
most common associated HLA locus is HLA DR4; among white North Americans and 
northern Europeans, susceptibility relates to the alleles DRB1-0301 and DRB1-0401 
(Hytiroglou et al, 2009; Hennes et al, 2008). Type 2 AIH, a rare disorder characterized by 
antibodies against liver-kidney microsome 1 and liver cytosol 1 has been associated with the 
HLA DRB1 and HLA DQB1 alleles (Djilali-Saiah et al 2004).  
Loss of self tolerance is the requisite for autoimmune disease, and it distinguishes autoimmune 
conditions from disorders associated with immunologic reactions to foreign antigens. The 
most promising considerations are defects in the negative selection of autoreactive 
immunocytes (Czaja, 2007c; Czaja & Carpenter, 2006) and clonal expansion of immunocytes 
cross-reactive to homologous antigens (molecular mimicry) (Hubscher, 2001; Prados et al, 
1998; Ayata et al, 2000). The negative selection removes thymocytes that are capable of 
strongly binding with self peptides presented by major histocompatibility complex (MHC). 
This process is an important component of immunological tolerance and serves to prevent the 
formation of self reactive T cells. According to experimental evidences the risk of autoimmune 
disease probably relates to actions of genes that limit this process (Czaja & Carpenter, 2006; 
Banff Working Group, 2006). Molecular mimicry has been proposed as pathogenetic 
mechanism for AIH. This hypothesis has been substantiated in experimental models by 
showing that the immunocytes can be activated by diverse but similar epitopes, and they can 
be clonally expanded to show a broad cross-reactivity. Such cells then can be directed against 
self-antigens that mimic foreign antigens (Hubscher, 2001; Prados et al, 1998; Ayata et al, 2000). 
Molecular mimicry is a useful concept to explain how different viruses, drugs or unknown 
environmental agents might produce a self-perpetuating hepatic injury with the same clinical 
expression. It also may explain how AIH recurs or develops de novo after liver 
transplantation. In addition, experimental evidences suggest that genetic polymorphisms 
affecting the cytokine microenvironment (Gonzales-Koch et al, 2001; Donaldson et al, 1991), 
immune regulators (Czaja et al, 1993a) and the mechanism of apoptosis (Czaja et al, 1997) 
could influence the immunocyte activation and perpetuate the immune response.  
The identification of CD4+ regulatory T cells has reinvoked the concept that failure of or 
escape from normal suppression of reactivity against the self has an essential role in the 
development of autoimmune disease. Recent experimental evidence suggests that 
immunoregulatory dysfunction characterized by decreased numbers of CD4+CD25+ 
regulatory T cells may occur in AIH (Longhi et al, 2004). 
2.1 Pathogenesis of recurrent AIH 
AIH recurs after liver transplantation in 11% to 83% of cases with considerable variation 
between studies depending on the diagnostic criteria applied. Many studies suggest that the  
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risk of recurrence increases with the time after transplantation (Birnabaum et al, 1997; 
Campsen et al, 2008; Prados et al, 1998; Sempoux et al, 1997). In an interesting study, Duclos-
Vallee et al. suggest that the histological recurrence of AIH may develop 1-5 years before the 
laboratory manifestations (Duclos-Vallee et al, 2003). 
The pathogenesis of recurrent AIH is uncertain, although it is widely accepted that a strong 
genetic predisposition may affect its occurrence, behavior and outcome (Czaja, 2008a), as 
well as its risk of recurrence (Czaja, 1999b, 2002, 2009). HLA mismatching between donor 
and recipient has been proposed as a factor in recurrent disease (Wright, 1992), but its 
importance continues to be disputed (Gonzales-Koch et al, 2001; Ayata et al, 2000; 
Milkiewicz, 1999, Reich, 2000, Devlin, 1995). Some authors suggest that matched rather than 
mismatched HLA may be a factor influencing the development and severity of the disease 
(Neumann et al, 2003; Futagawa & Terasaki, 2004). In this instance, it seems that similar 
class II MHC molecules between donor and recipient can intensity the autoreactive 
response. 
HLA DRB1*03 is present in over 70% of the recipients who experience recurrence (Gonzales-
Koch et al, 2001), and the DRB1*0301 allele may be a factor in promoting disease severity 
before transplantation (Czaja, et al, 1997) and disease recurrence after transplantation 
(Gonzales-Koch et al, 2001, Czaja, 2008b, Devlin et al, 1995). Other autoimmune promoters 
might include gene polymorphisms that alter the cytokine microenvironment (Czaja et al, 
1999a) or involve polymorphisms of genes affecting immunocyte activation, such as those 
encoding cytotoxic T lymphocyte antigen-4 (Agarwal, 2000). Furthermore, the female 
predisposition for recurrent AIH suggests that an acquired preferential X chromosome 
inactivation (that has been described in primary biliary cirrhosis) may also be important 
(Miozzo et al, 2007). Potential associations with loci in other chromosomes are under 
investigation (Fukagawa et al, 2001; Vogel et al, 2002).  
The donor liver may contain antigenic substrates against which the recipient-derived 
immunocytes can react, and these substrates could be normal components that share 
homologies with other self-antigens within the recipient (Czaja, 2002). The structural and 
conformational homologies between antigenic targets within the donor liver and those 
within the recipient might provoke a promiscuous T cell response through molecular 
mimicry.  
Knowledge concerning antigenic targets responsible for initiating the cascades of events in 
recurrent AIH is still rudimentary. A leading candidate has been the asialoglycoprotein 
receptor, a surface membrane protein. Hepatocytic microsomal enzymes, such as CYP2D6, 
and cytosolic components, such as transfer ribonucleoprotein complexes, are also under 
investigation (Czaja, 2002). Professional antigen presenting cells exist outside the liver, and 
antigenic peptides can be presented and subsequently processed independently of the graft 
(Obhrai, 2006; Bell & Westermann, 2008; Vierling, 1999). T cell subsets, cross-reactive to 
homologous hepatic antigens, could be expanded by the presentation of donor antigens on 
recipient-derived antigen-presenting cells that replace those of the donor liver (Vierling, 
1999). The rapidity of this replacement and the number of antigen-presenting cells in the 
recipient lymph nodes and spleen might affect the timing and severity of the recurrence 
(Czaja, 2002). 
Promiscuous T cells that have been primed to react to molecular homologies are probably 
already present within the recipient (Sprent, 1993; Vierling, 1999), and the appearance and 
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severity of recurrent AIH simply reflect the dose of antigenic targets within the donor liver 
(Czaja, 2002). Alternatively, the immunological response may be newly created by 
protracted exposure to donor-derived hepatic antigens (Czaja 2002, 2009). This hypothesis 
suggests that recurrent AIH could reflect an immune response against donor liver antigens 
that is not HLA-restricted (Czaja, 2002). The class II MHC molecules within the donor liver 
could directly activate the immunocytes of the recipient and generate a response that is not 
dependent on the presentation of antigenic peptide or HLA matching (Vierling, 1999). In 
this instance, the MHC molecules of the donor liver would be the antigenic targets and HLA 
restrictions on immunocyte activation would be overridden. 
Components of the Autoreactive 
Response 
Putative Mechanisms 
Class II MHC molecules Present autoantigen to T helper lymphocyte 
Initiate immunocyte activation 
HLA susceptibility alleles 
 
Encode structure of the antigen binding 
groove of the class II MHC molecule 
Determine optimal autoantigen for 
presentation 
DRB1*03 in white North Americans 
Professional antigen presenting cells 
 
Macrophages and dendritic cells 
Exist outside the liver within the recipient 
Re-populate the donor liver after 
transplantation 
Donor liver autoantigens Promote promiscuous T cell response 
against homologous targets in the donor 
liver, such as microsomal antigens 
(CYP2D6, UDGT), cytosolic components 
(ribonucleoprotein complexes), surface 
membrane receptors (asialoglyoprotein 
receptor), class II MHC molecules, or 
superimposed viral antigens 
Promiscuous T lymphocytes Target multiple antigens in the donor liver 
that resemble the original activating epitope 
Retain long memories for the antigenic 
target 
Re-invigorate after long dormancy 
Counter-regulatory cytokines or 
regulatory T cell populations 
Facilitate autoreactivity by reduced 
suppressive actions 
Abbreviations: CYP2D6, cytochrome 2D6; HLA, human leukocyte antigen; MHC, major histocompatibility 
complex; UDGT, uridine diphosphate glucuronosyltransferase 
Table 1. Pathogenic Mechanisms of Recurrent Autoimmune Hepatitis 
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Viral infections are another source of antigenic homologies that may activate promiscuous T 
cells (Czaja, 2002) (Table 1). The genomic sequences of hepatitis C virus, herpes simplex 
virus, and cytomegalovirus have homologies with CYP2D6 (Manns et al, 1991; Ma et al, 
2006), and other mimicries between viral and self-antigens undoubtedly exist that can 
trigger recurrent AIH (Vergani et al, 2002; Bogdanos et al, 2001). Viruses may also produce 
an inflammatory process within the graft that may resemble the recurrent AIH. An anti-
graft response against a viral antigen may be indistinguishable from an autoimmune 
response, and the recurrent AIH in this instance could represent a normal immune response 
against an unsuspected viral agent in an immunosuppressed host (Vierling, 1999). The 
complexity and inner connectivity of the counter-regulatory mechanisms that must be 
disrupted to cause recurrent AIH allows broad speculation about the triggering events and 
the factors which perpetuate the disease (Czaja 2002, 2008b).  
Another factor related to the recurrence of AIH is represented by the net state of 
immunosuppression. Corticosteroid withdrawal, adjustments in the dose and nature of the 
immunosuppressive drugs (cyclosporine, tacrolimus, and mycophenolate mofetil), acute 
and chronic rejection, superimposed infection, and drug toxicities are post-transplantation 
events that have all been implicated in the recurrence of AIH (Hubscher, 2001; Neuberger, 
2002; Schreuder et al, 2009). Recurrence has been associated with reduction in the doses of 
immunosuppressive medication, especially corticosteroids (Neuberger et al, 1984; Gonzalez- 
Koch et al, 2001; Prados et al, 1998; Khalaf et al, 2007). These observations indicate that the 
pathogenic mechanisms of AIH are perpetuated after liver transplantation and that they can 
be suppressed but not eradicated by treatment schedules that are properly dosed (Czaja, 
1999b). Recent studies, however, have indicated that the requirement for corticosteroid 
suppression may not be permanent after liver transplantation and that corticosteroid 
therapy can be successfully withdrawn in 50-68% of patients (Campsen et al, 2008; Trouillot 
et al, 1999). There is evidence that AIH recurs in 35% of individuals withdrawn from 
corticosteroids, but the recurrence has not been associated with discontinuation of the 
medication by multivariate analysis (Campsen et al, 2008). These findings do not discount 
the earlier observations that corticosteroid withdrawal or dose reduction contributes to 
disease recurrence, but they suggest that successful withdrawal is possible if the effort is 
persistent, individualized and well-timed (Czaja, 1999b). 
Patients transplanted for AIH have a higher frequency of acute and chronic rejection (81% 
versus 47%, p<0.001) and corticosteroid-resistant rejection (38% versus 13%, p=0.003) than 
patients transplanted for other conditions (Vogel et al, 2004; Hayashi et al, 1998), and in one 
series, the frequency of acute cellular rejection was higher (33% versus 14%) than in other 
transplanted patients from the same institution and from other institutions (33% versus 4%) 
(Czaja, 1999b; Trouillot et al, 1999). The propensity for acute and chronic cellular rejection 
may reflect an intrinsic immune hyper-reactivity within the patient with AIH (Czaja, 1999b). 
Alternatively, rejection may be the basis for releasing hepatic antigens that sensitize the 
susceptible individual and trigger the recurrence (Czaja, 2009). Patients with recurrent AIH 
have a higher frequency of rejection during the first 3, 6 and 12 months after transplantation 
than patients without recurrent disease, but previous rejection is not a requisite for 
recurrence (Molmenti et al, 2002). Another factor that has been implicated in recurrence has 
been the calcineurin inhibitors used in the immunosuppressive regimen after 
transplantation (Schreuder et al, 2009; Gautam et al, 2006). Cyclosporine and tacrolimus may 
have paradoxical effects which can promote the autoreactive response. Cyclosporine inhibits 
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signal transduction from the engaged T cell antigen receptor (Hess et al, 2001), and it may 
also have a direct toxic effect on the thymic stroma (Beschorner et al, 1988). These actions 
may alter the editing of T lymphocytes within the thymus and impair the negative selection 
of autoreactive cells. Furthermore, the impairment of T cell antigen receptor signaling can 
prevent the apoptosis of autoreactive lymphocytes which can in turn extend their survival 
(Lotem et al, 1999; Wang et al, 1999). Tacrolimus affects the thymic microenvironment in a 
fashion like cyclosporine, and it might also paradoxically enhance immune reactivity 
(Cooper et al, 1991). These theoretical considerations have not been established in human 
disease (Gautam et al, 2006), and both medications have been used successfully in the 
treatment of recurrent AIH (Hubscher, 2001). Nevertheless, the failure of recurrent AIH to 
respond to one calcineurin inhibitor might warrant institution of the other (Hurtova et al, 
2001). 
Risk Factor Theoretical Consequences 




Corticosteroids are withdrawn 
Immunosuppressive regimens 
are reduced 
Acute or chronic cellular rejection 
occurs 
Drug toxicity develops 
Viral infection superimposed 
Corticosteroid withdrawal Facilitates autoimmune response 
Reduced immunosuppression Facilitates autoimmune response 
Acute or chronic rejection Releases hepatic antigens 
Invigorates promiscuous 
lymphocytes 
Calcineurin inhibitor Reduces thymic negative 
selection of immunocytes 




HLA matching or mismatching Intensifies autoreactive response 
Female gender 
 
Acquired preferential X 
chromosome inactivation 
Impairs mechanisms that protect 
self-tolerance 
Severity of original disease Immune reactivity persists post-
transplant 
Genetic predisposition for severe 
disease facilitates recurrence 
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The severity of the original liver disease may also be a factor in disease recurrence after liver 
transplantation. Patients with recurrent AIH have higher serum levels of immunoglobulin G 
and histological findings of plasma cell infiltration and severe inflammatory activity more 
often immediately prior to transplantation than patients without recurrence (Montano-Loza 
et al, 2009). These observations suggest that recurrent AIH is a continuum of the original 
disease or a newly created process in a susceptible host with a propensity for severe 
immune reactivity (Czaja, 2009). They imply that aggressive disease suppression 
immediately prior to transplantation might alter the consequences after transplantation 
(Montano-Loza et al, 2009) or that an vulnerable individual may be identified early who 
warrants close surveillance after transplantation (Czaja, 2009). Most likely, the intrinsic 
bases for recurrent AIH interact with the extrinsic factors to define the true risk. 
2.2 Pathogenesis of de novo AIH  
De novo AIH is a late complication that develops in patients undergoing transplantation for 
nonautoimmune liver disease (Czaja, 2002, 2007b). Since its first description by the King’s 
College group (Kerkar et al, 1998), it has been widely reported in both adult and child 
recipients after deceased or living liver donor (Hernandez et al, 2001; Gupta et al, 2001; 
Henegan et al, 2001; Salcedo et al, 2002; Aguilera et al, 2001; Miyagawa et al, 2004; Inui et al, 
2005; Venick et al, 2007; Di Cocco et al, 2008). The frequency of de novo disease may be 
increased because the population at risk is exposed to a great number of risk factors. 
Children seem to have a predilection for the syndrome (Birnbaum et al, 1997; Campsen et al, 
2008; Duclos-Valle et al, 2003; Yao et al, 2007; Czaja & Freese, 2002) and immunosuppression 
with cyclosporine is a common feature (Birnbaum et al, 1997; Pappo et al, 1995; Czaja & 
Freese, 2002). 
Pathogenic mechanisms involved in the de novo AIH probably are the same as those 
responsible for the disease before transplantation. Impaired negative selection of 
autoreactive immunocytes and molecular mimicry are still the principal pathogenic 
considerations, but their emergence as initiators of disease must be analyzed within the 
context of the clinical setting. Immunosuppressive therapy and exposure to diverse 
pathogens after transplantation may severely compromise the ability of an immune system 
already weakened by chronic illness and/or immaturity to preserve self tolerance.  
Cyclosporine inhibits signal transduction from the engaged T-cell antigen receptor (Ayata et 
al, 2002) and also may have a direct toxic effect on the thymic stroma (Seyam et al, 2007). 
These actions may alter the editing of T lymphocytes within the thymus and impair the 
negative selection of autoreactive cells. Impairment of T cell antigen-receptor signaling can 
prevent the apoptosis of class II MHC-restricted autoreactive lymphocytes, which in turn 
may leak into the peripheral compartment and be intolerant of self. Cyclosporine inhibits 
the calcineurin-mediated pathway in the signaling of the apoptosis, and in this fashion, it 
may extend the survival of autoreactive cells (Czaja, 1999b, 2007b; Khalaf et al, 2007). Active 
immune mediated lesions within the colon, liver, stomach, and pancreas have been 
described in an animal model treated with cyclosporine, and the findings constitute 
cyclosporine-induced autoimmune disease (Trouillot et al, 1999).  
A T-cell-dependent autoaggressive disease also has been reported after syngenic and/or 
autologous bone marrow transplantation in recipients treated with cyclosporine (Hayashi et 
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al, 1998), and it may reflect cyclosporine-induced failure of T-lymphocytes to recognize class 
II MHC antigens as self (Gautam et al, 2006; Hess et al, 2001). Pretreatment of animal models 
of bone marrow transplantation with monoclonal antibodies against class II MHC 
determinants prevents adoptive transfer of syngenic graft-versus-host disease, whereas 
antibodies against class I MHC antigens are unable to prevent this outcome (Beschorner et 
al, 1988; Lotem et al, 1999). Tacrolimus affects the thymic microenvironment in a fashion like 
cyclosporine, and it also can induce a graft-versus-host-like reaction after syngenic bone 
marrow transplantation in rats (Cooper et al, 1991). These observations suggest that such 
immunosuppressive drugs (cyclosporine and tacrolimus) may have paradoxical effects in 
some liver transplant patients. Immunosuppression is the desired primary action, but 
enhanced autoreactivity may be a secondary consequence in some individuals. Young 
patients with immature immune system would logically be most vulnerable for the 
autoimmune response and most instances of de novo AIH have been reported in the 
pediatric group. An active thymus, immature T-cell-antigen receptor repertoire and 
repeated exposure to multiple homologous infectious and/or drug-related antigens would 
be likely additional requisites for de novo disease. 
Importantly, no conclusive data show that cyclosporine or tacrolimus induce AIH in 
humans, and both medications have been used successfully to treat classic AIH in adults 
and children (Cooper et al, 1991; Hurtova et al, 2001; Czaja, 2008; Wright et al, 1992; Reich et 
al, 2000; Devlin et al, 1995). Furthermore, animal models of cyclosporine-induced AIH have 
been highly perturbed models that may have no clinical relevance (Trouillot et al, 1999). 
3. Clinical features and diagnostic criteria  
AIH is an inflammatory process of unknown cause that is characterized by increased serum 
aspartate (AST) and alanine (ALT) aminotransferase levels, hypergammaglobinemia, 
autoantibodies, and interface hepatitis on histological examination (Krawitt, 2006; Czaja & 
Freese, 2002). Immunoglobulin G is the predominant serum γ-globulin component that is 
abnormally increased, and the typical autoantibodies associated with the disease are 
antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and antibodies to liver 
kidney microsome type 1 (anti-LKM1) (Czaja, 2007b). 
Antinuclear antibodies and SMA tend to cluster together, and they are not commonly 
expressed in association with anti-LKM1 (Homberg et al, 1987; Czaja et al, 1992; Czaja, 
1999a). This mutual exclusivity has justified the designations of type 1 AIH to identify the 
disease associated with ANA and SMA and type 2 AIH to identify the disease associated 
with anti-LKM1 (Czaja & Manns, 1995). These terms have not been endorsed by the 
International Autoimmune Hepatitis Group (IAIHG) since the serological types may not be 
distinct pathological entities (Alvarez et al, 1999). Nevertheless, the designations have been 
useful descriptors in clinical practice and in research studies, and they have become 
entrenched in the terminology of the disease. The same basic features of AIH in the native 
liver have characterized recurrent AIH in the transplanted liver. 
Transplant recipients with AIH are younger and more commonly women than other 
transplant recipients (Molmenti et al, 2002), and they have HLA DRB1*03 more frequently 
(Sanchez-Urdazpal et al, 1992; Gonzalez-Koch et al, 2001). HLA DRB1*03 and DRB1*04 are 
the principal susceptibility factors for AIH in white North American and northern European 
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patients (Donaldson et al, 1991), and HLA DRB1*03 has been associated with early age of 
disease onset and a higher frequency of treatment failure than patients with other HLA 
(Czaja et al, 1993, 1997; Czaja & Carpenter, 2006). The same clinical phenotype that has 
typified AIH in native patients also characterizes the patients who develop recurrent disease 
after transplantation (Gonzalez-Koch et al, 2001; Hubscher, 2001). In de novo AIH, Salcedo 
et al. found a significant increase in the prevalence of HLA DR3 and a trend to higher 
frequencies for HLA-B8, -DR15, -DR51 and –Q6 (Salcedo et al, 2002). Symptoms may vary 
from none to severe (jaundice and hepatic failure), and the presence of disease must be 
actively sought in asymptomatic patients by the regular monitoring of liver indices (serum 
AST, ALT, bilirubin, and γ-globulin levels) and protocol liver biopsies (Pappo et al, 1995; 
Duclos-Vallee et al, 2003; Yao et al, 2007).  
Type Feature Frequency 
Clinical Female Common 
 Young Common 
 Asymptomatic Common 
 Jaundice Rare 
Laboratory Increased Serum AST/ALT Required 
 Increased Serum γ-globulin  Usual 
 Increased Serum immunoglobulin G Usual 
 HLA DRB1*03 Common (ethnic dependent) 
 No viral markers Required 
Serological ANA/SMA  Common 
 Anti-LKM1 Possible 
Histological Interface hepatitis Required 
 Plasma cell infiltration Common 
 Lobular hepatitis Rare 
 Acidophil bodies Rare 
 Mixed features Possible 
 Non-specific hepatitis Possible 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ANA, antinuclear 
antibodies; anti-LKM1, antibodies to liver/kidney microsome type 1; HLA, human leukocyte antigen; 
SMA, smooth muscle antibodies 
Table 3. Clinical Features of Recurrent Autoimmune Hepatitis After Liver Transplantation 
The importance of autoantibodies in the diagnosis of recurrent and de novo AIH is still 
debated. The majority of patients in whom a diagnosis of recurrent AIH is made have 
positive autoantibodies. However, several studies have shown that autoantibodies persist in 
the majority of patients who undergo transplantation for AIH, generally at lower titers than 
before liver transplantation, irrespective of other features suggestive of disease recurrence 
(Ahmed et al, 1997; Prados et al, 1998; Gotz et al, 1999; Reich et al, 2000). This is analogous to 
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the situation that exists for patients undergoing liver transplantation for primary biliary 
cirrhosis; most remain positive for antimitochondrial antibodies without necessarily having 
other features to suggest disease recurrence (Esquivel et al, 1988; Mattalia et al, 1997). One 
study suggested that the presence of autoantibodies in titers exceeding pretransplantation 
levels may be the manifestation of recurrent AIH (Reich et al, 2000) but this observation, 
based on small number of cases requires further confirmation. It is possible as suggested by 
Gonzales-Koch et al., that the formation of autoantibodies may be impaired in the setting of 
immunosuppression (Gonzales-Koch et al, 2001). Impaired antibody formation after liver 
transplantation is well recognized in hepatitis C virus (HCV)-positive patients, many of 
whom have high viral RNA levels without detectable anti-HCV antibodies (Poterucha et al, 
1992; Hsu et al, 1994).  
Autoantibodies arising de novo after liver transplantation have also been noted in 
association with episodes of rejection (Duclos-Valle et al, 2000). Classic autoantibodies are 
commonly present in the serum of these patients but atypical serum autoantibodies are 
characteristically observed (Alvarez et al, 1999; Hubscher, 2001). Among these atypical 
antibodies, one antibody type seems to be direct against the cytosolic enzyme glutathione S-
transferase T1. Interestingly GSTT1 mismatch between the donor and the recipient has been 
reported as a prerequisite for the development of de novo AIH after liver transplantation 
(Aguilera et al, 2001; Inui et al, 2005). In addition the early detection of anti-GSTT1 
antibodies may help to identify a subset of patients at risk of developing de novo AIH 
(Salcedo et al, 2009).  
Several studies have shown the important role of the routine liver biopsies in the diagnosis 
of AIH without biochemical evidence of hepatitis (Ahmed et al, 1997; Prados et al, 1998; 
Gotz et al, 1999). Interface hepatitis is the histological hallmark of recurrent AIH after 
transplantation, and plasma cell infiltration is a feature of the disease (Gonzalez-Koch et al, 
2001; Hubscher, 2001; Ayata et al, 2000; Banff Working Group et al, 2006) Concurrent 
immunosuppressive therapy can modify the nature and severity of the inflammatory 
infiltrate, and the histological diagnosis may be based on more subtle changes than those 
observed in the native disease (Gonzalez-Koch et al, 2001; Hubscher, 2001). Plasma cell 
infiltration is neither specific nor required for the diagnosis of recurrent AIH (Banff Working 
Group et al, 2006). Acidophil bodies in conjunction with lymphoplasmacytic infiltrates are 
seen in early recurrent AIH (Ayata et al, 2000), and an acute lobular hepatitis is also 
compatible with the diagnosis (Ayata et al, 2000; Sempoux et al, 1997). The histological 
changes of acute or chronic rejection may occur simultaneously with those of AIH, and 
concurrent pathological processes must be considered when confusing mixed and atypical 
histological features are present (Pappo et al, 1995; Hytiroglou et al, 2009). 
The histological findings of de novo AIH may differ from the interface hepatitis usually 
found in the classic AIH (Gupta et al, 2001). In de novo AIH there is histological evidence of 
portal and periportal hepatitis with or without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate with a variable degree of plasma cells. Histological 
features of bile ductular proliferation and markedly increased serum concentrations of 
gamma glutamyl transpeptidase suggest the likelihood of treatment failure and probably 
indicate a variant syndrome of AIH (Campsen et al, 2008; Berg et al, 2002). De novo disease 
in some adults has been associated with severe centrilobular necrosis that may confound 
diagnosis and adult patients have been reported to express an atypical antiliver/kidney 
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cytosolic antibody of uncertain pathogenic significance (Czaja, 2007b). This antibody reacts 
to rat hepatocyte cytoplasm, chiefly in the centrilobular area, and also shows indirect 
immunofluorescence in distal and proximal tubules of rat kidney (Czaja, 2007b). 
The diagnostic guidelines (Alvarez et al, 1999), not tested in patients receiving 
immunosuppressive therapy, cannot be used with confidence in the post-transplantation 
setting (Hubscher, 2001; Li & Neuberger, 2009; Neuberger, 2002; Duclos-Valle, 2005; 
Schreuder et al, 2009). As stated before, the diagnosis of recurrent and de novo AIH 
requires the presence of compatible clinical, laboratory and histological findings, and it 
depends mainly on the exclusion of other conditions that can resemble it (Milkiewicz et al, 
1999).  
Acute or chronic cellular rejection is the main diagnosis that must be excluded (Banff 
Working Group et al, 2006; Lefkowitch, 2002). The key clinical distinctions between AIH 
after liver transplantation and acute cellular rejection are time to disease onset, HLA 
DRB1*03 status, and autoantibody production. Recurrent autoimmune hepatitis develops 
after a median interval of 2 years (Czaja, 2002, 2009; Gonzalez-Koch et al, 2001), whereas 
acute cellular rejection typically develops within 6 weeks after transplantation with a 
median interval of 8 days (Wiesner et al, 1998). Patients with recurrent AIH commonly have 
HLA DRB1*03, and they have autoantibodies of substantial titer (Sanchez-Urdazpal et al, 
1992; Gonzalez-Koch et al, 2001). The major histological distinctions between recurrent AIH 
and acute cellular rejection are the moderate-severe interface hepatitis and plasma cell 
infiltration that characterize AIH, and the eosinophils, endotheliitis, and cholangitis that 
characterize acute cellular rejection (Lefkowitch, 2002). 
Autoimmune hepatitis and chronic rejection each occur months after transplantation, but 
this is their only point of resemblance. Each condition should be easily distinguished from 
the other as cholestasis, portal ductopenia, centrilobular fibrosis, and foam cell arteriopathy 
characterize chronic rejection (Banff Working Group et al, 2006; Lefkowitch, 2002). The 
principal pathogenic distinctions between the recurrent AIH and the rejection responses 
probably relate to the origin of the antigen-presenting cells that initiate the immune 
response and the nature of the antigens that are targeted by the activated immunocytes. The 
autoimmune response requires re-population of the donor liver with antigen-presenting 
cells (such as dendritic cells and macrophages) from the recipient. The presentation of self-
antigens common to both the donor and recipient can initiate the autoimmune response in 
the donor liver. In contrast, the rejection response is based on the reactivity of promiscuous 
cytotoxic T lymphocytes from the recipient against foreign antigens presented by the donor 
liver, including class II MHC molecules, viral proteins, and novel donor organ antigens 
(Czaja, 2002; Vierling, 1999). 
Plasma cell hepatitis and isolated central perivenulitis can also confuse the diagnosis of 
recurrent AIH. Each condition is probably a variant of rejection. Plasma cell hepatitis does 
not improve with corticosteroid treatment; it may develop as immunosuppressive therapy is 
reduced; and it improves as the immunosuppressive regimen is intensified (Demetris & 
Sebagh, 2008; Fiel et al, 2008). Isolated central perivenulitis can be found in 28% of allografts, 
and it can lead to de novo autoimmune hepatitis or chronic liver injury, especially if it 
occurs late after transplantation (Krasinskas et al, 2008). Typically, perivenulitis is untreated, 
but this approach is debated and anti-rejection therapy has been proposed. 
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Diagnosis Distinctive Features 
Recurrent autoimmune hepatitis Late onset (median, 2 years) 
Interface hepatitis 
Plasma cell infiltration 
Autoantibodies (serum titer ≥1:320) 
HLA DRB1*03 (ethnic dependent) 
Acute cellular rejection Early onset (median, 8 days) 
Endotheliitis 
Cholangitis (histological finding) 
Eosinophilic infiltrates 
Chronic cellular rejection Late onset (range, 3-8 months) 
Cholestasis (histological finding) 
Portal ductopenia 
Centrilobular fibrosis 
Foam cell arteriopathy 
Plasma cell hepatitis Rejection variant 
Associated with reduced 
immunosuppression 
Unresponsive to corticosteroids 
Improves with increased 
immunosuppression 
Isolated central perivenulitis Rejection variant 
Progressive if late occurrence 
May result in autoimmune hepatitis 
Hepatitis C virus infection Portal lymphoplasmacytic response possible 
Serological markers of active viremia 
De novo AIH Late onset (median, 2 years)  
Children predilection 
Interface hepatitis 
Portal and periportal hepatitis with or 
without centrilobular necrosis and 
lymphoplasmacytic portal tract infiltrate  
Autoantibodies (classic and atypical) 
Response to prednisone and azathioprine 
Table 4. Differential Diagnosis of Recurrent and De Novo AIH After Transplantation 
Superimposed viral infections, especially HCV, must always be excluded in patients with 
graft disruption after transplantation because may elicit a pronounced lymphoplasmacytic 
response within the portal tract that can be difficult to distinguish from recurrent AIH (Banff 
Working Group et al, 2006; Demetris & Sebagh, 2008). Furthermore, recurrent AIH and HCV 
infection may occur together in the same allograft (Pappo et al, 1995). A comprehensive 
virological assessment is warranted to exclude infection in all patients with features of 
recurrent AIH after transplantation. 
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The absence of reliable diagnostic markers for recurrent AIH has compelled reliance on the 
histological findings to support the diagnosis, and the features of nonspecific chronic 
hepatitis have been the minimal bases for the diagnosis in some cases (Hubscher, 2001). 
Seronegative AIH has been described in native patients (Czaja et al, 1993; Gassert et al, 2007; 
Heringlake et al, 2009), and there is an emerging experience that suggests that it may be a 
relevant consideration in patients with graft dysfunction after liver transplantation 
(Nakhleh et al, 2005; Berg et al, 2002; Ayata et al, 2002; Seyam et al, 2007). Most patients who 
undergo liver transplantation for cryptogenic chronic hepatitis can be classified into 
conventional diagnostic categories after review of their liver tissue specimens before and 
after liver transplantation, but 15% remain cryptogenic and at risk for disease recurrence 
and progression (Ayata et al, 2002). 
Cirrhosis may develop after transplantation in seronegative patients with recurrent 
histological features of chronic hepatitis, especially in those patients transplanted for 
seronegative fulminant hepatitis, and the possibility of recurrent seronegative AIH cannot 
be excluded in these individuals (Seyam et al, 2007). Consequently, recurrent AIH should be 
considered in all patients with acute and chronic graft dysfunction after liver 
transplantation. The diagnostic criteria must accommodate the atypical manifestations 
encountered after transplantation that may reflect superimposed medication effects and 
diverse other diseases associated with the transplantation. 
4. Outcome 
Recurrent AIH is typically a mild inflammatory process in an asymptomatic individual who 
has been inadequately immunosuppressed after transplantation or prematurely withdrawn 
from corticosteroids (Gonzalez-Koch et al, 2001; Prados et al, 1998; Neuberger, 2002; Khalaf, 
2007). Recurrent disease usually responds to the re-introduction of corticosteroid therapy or 
adjustments in the doses of the original immunosuppressive agents (Gonzalez-Koch et al, 
2001; Faust, 2000, 2001). The frequency of recurrence does not correlate with the frequency 
of graft loss, and patient and graft survivals after recurrence have been similar to those of 
other transplanted diseases (Li &Neuberger, 2009; Schreuder, 2009). Survival in patients 
with recurrent disease has ranged from 78-89% (Vogel et al, 2004; Yusoff et al, 2002). 
Progression to cirrhosis and graft loss can occur (Milkiewicz et al, 1999; Ratziu et al, 1999; 
Rowe et al, 2008), and recurrent AIH with graft loss after the second transplantation has been 
reported (Reich et al, 2000). Furthermore, not all patients with recurrent AIH are inadequately 
immunosuppressed at the time of presentation (Ratziu et al, 1999) or responsive to the re-
institution of corticosteroid therapy (Prados et al, 1998; Neuberger, 2002). Patients with severe, 
aggressive recurrent AIH have not been fully characterized, and the individuals at risk for a 
dire outcome cannot be reliably identified. The serological type of the original disease may 
affect the need for transplantation (Cattan et al, 2002), but it does not correlate with prognosis 
after transplantation (Vogel et al, 2004). Similarly, the severity of the disease at transplantation 
does not predict outcome after the procedure (Montano-Loza et al, 2009). Patients transplanted 
for fulminant AIH have lower frequencies of recurrence after transplantation and better 
survivals than patients transplanted for chronic AIH (Reich et al, 2000; Nunez-Martinez et al, 
2003), but most patients who develop recurrent AIH do not have fulminant presentations. The 
outcome of de novo AIH remains largely unknown, but several cases with severe liver damage 
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and hepatic failure leading to death have been described (Hernandez et al, 2001), indicating 
the needing for specific management of this complication.  
5. Treatment 
The first course of action is to establish the correct diagnosis, reassess the adequacy of the 
immunosuppressive regimen, and determine the compliance of the patient. Measurement 
of the drug metabolites in blood may be necessary to ensure the adequacy of dosing and 
the compliance of the individual (Rumbo et al, 2004). The second course of action is to 
optimize the doses of the conventional immunosuppressive medication and to re-
introduce corticosteroids if they have been withdrawn (Neuberger, 2002). Treatment with 
prednisone and azathioprine is typically effective in recurrent (Birnbaum et al, 1997; 
Pappo et al, 1995; Duclos-Vallee et al, 203; Czaja & Freese, 2002; Czaja, 2007b) and de novo 
AIH (Salcedo et al, 2002). Failure to respond or disease progression despite compliance 
with therapy justifies a closely monitored empiric trial with alternative 
immunosuppressive agents. The calcineurin inhibitor could be changed to another drug in 
this same category (Hurtova et al, 2001); a purine antagonist (azathioprine or 
mycophenolate mofetil) could be added or its dose optimized (Rumbo et al, 2004); or 
rapamycin, which is a mTOR (mammalian target of rapamycin) inhibitor, could be 
introduced (Kerkar et al, 2005). These agents have been reported as effective salvage 
therapies in small single-center case reports, but none have been established by large 
multicenter experiences or organized clinical trials. Patients in whom therapy fails have 
worsening fibrosis and possible graft loss (Vogel et al, 2004; Campsen et al, 2008) and 
those not administered corticosteroids progress to cirrhosis, require re-transplantation or 
die of liver failure (Czaja, 2007b). Re-transplantation must be considered if the disease 
continues to progress with the understanding that the disease could recur in the second 
graft and again jeopardize its survival (Reich et al, 2000). 
6. Summary 
AIH commonly recurs after liver transplantation, and asymptomatic histological recurrence 
may precede clinical recurrence by 1-5 years. Acute and chronic cellular rejection, drug 
toxicity, and viral infection must be confidently excluded, and treatment typically requires 
adjustment in the doses of immunosuppressive medication or the re-institution of 
corticosteroid therapy. Empiric treatments with another calcineurin inhibitor, purine 
antagonist (azathioprine or mycophenolate mofetil), or mTOR inhibitor (rapamycin) are 
available for refractory disease, and re-transplantation may be necessary. 
Future studies are needed to codify diagnostic criteria, define risk factors that are predictive 
of recurrence and its progression, standardize surveillance schedules after transplantation, 
develop a uniform management algorithm, and elucidate mechanisms of disease. 
Insights into the pathogenesis of recurrent and de novo AIH may elucidate a similar 
behavior in the native disease. Native AIH also exacerbates frequently after corticosteroid 
withdrawal, and this flare may occur after long intervals of quiescence. The concepts that 
activated immunocytes can trigger the same disease after a long dormancy or that a 
susceptible host with a genetic predisposition can develop newly created episodes of the 
same disease may apply to both conditions. The experiences in liver transplantation have 
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much to teach about AIH, and future investigations that clarify the mechanisms of recurrent 
and of de novo AIH will have broad implications for autoimmune diseases in general, not 
only for classical AIH. Future investigations must continue to utilize the human 
transplantation experience to elucidate the key mechanisms of the autoimmune response in 
the native liver. 
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